Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

8.2%

12 terminated/withdrawn out of 146 trials

Success Rate

91.4%

+4.9% vs industry average

Late-Stage Pipeline

29%

42 trials in Phase 3/4

Results Transparency

27%

35 of 128 completed trials have results

Key Signals

2 recruiting35 with results9 terminated

Enrollment Performance

Analytics

Phase 1
87(64.0%)
Phase 3
36(26.5%)
N/A
6(4.4%)
Phase 4
6(4.4%)
Phase 2
1(0.7%)
136Total
Phase 1(87)
Phase 3(36)
N/A(6)
Phase 4(6)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (146)

Showing 20 of 146 trials
NCT06847724Phase 3Recruiting

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

Role: lead

NCT06153238Phase 1Active Not Recruiting

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

Role: lead

NCT01733082Recruiting

The Mycophenolate Pregnancy Registry

Role: collaborator

NCT06159790Phase 3Completed

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT06587451Phase 3Terminated

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Role: lead

NCT07223294Phase 3Not Yet Recruiting

Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma

Role: lead

NCT05633771Active Not Recruiting

Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting

Role: lead

NCT05258747Phase 1Completed

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Role: lead

NCT05070650Phase 3Withdrawn

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

Role: lead

NCT01766934Completed

Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors

Role: lead

NCT04864834Phase 3Completed

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

Role: lead

NCT00537914Phase 4Completed

Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)

Role: lead

NCT05887843Phase 1Terminated

Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis

Role: lead

NCT05590598Phase 3Completed

Efficacy and Safety of Azelastine +Mometasone , Nasal Spray, 140 mcg + 50 mcg, (Sandoz d.d., Slovenia) and Momat Rino Advance, Nasal Spray, 140 mcg + 50 mcg, (Glenmark, India) Administered as a Monotherapy to Patients With Seasonal Allergic Rhinitis.

Role: lead

NCT05588804Phase 3Completed

Study of the Efficacy and Safety of Broncho-munal®, Capsules, 7 mg for the Treatment of Acute Uncomplicated Respiratory Tract Infections

Role: lead

NCT05311475Phase 3Completed

Prospective, Randomized, Multinational, Multicenter, Double-blind, Placebo and Active Controlled Trial in 4 Parallel-groups of Patients Suffering From Seasonal Allergic Rhinitis

Role: lead

NCT00666835Phase 3Completed

Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

Role: lead

NCT04085809Not ApplicableCompleted

This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter Cosmetic

Role: lead

NCT05282004Phase 3Completed

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

Role: lead

NCT03974100Phase 3Completed

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

Role: lead